Summarized by Masters of Longevity from PR Newswire.
A news article about a medtech company joining a major research program to test a wearable system for continuous immune and autonomic monitoring in critical care patients, offering readers an inside look at the study's aims and how the technology will be evaluated.
Key Takeaways
- InflammaSense will deploy its VITAL x-patch wearable to monitor autonomic and inflammatory signatures in up to 200 critically ill patients.
- Data from the wearable will feed the company's ARC cascade-endotyping classifier to stratify patients by immune trajectory.
- InflammaSense participates as a subaward performer under the University of Vermont within ARPA-H's CIRCLE program funded up to $38 million.
